Literature DB >> 29418019

New Developments in Genetic rat models of Parkinson's Disease.

Rose B Creed1, Matthew S Goldberg1.   

Abstract

Preclinical research on Parkinson's disease has relied heavily on mouse and rat animal models. Initially, PD animal models were generated primarily by chemical neurotoxins that induce acute loss of dopaminergic neurons in the substantia nigra. On the discovery of genetic mutations causally linked to PD, mice were used more than rats to generate laboratory animals bearing PD-linked mutations because mutagenesis was more difficult in rats. Recent advances in technology for mammalian genome engineering and optimization of viral expression vectors have increased the use of genetic rat models of PD. Emerging research tools include "knockout" rats with disruption of genes in which mutations have been causally linked to PD, including LRRK2, α-synuclein, Parkin, PINK1, and DJ-1. Rats have also been increasingly used for transgenic and viral-mediated overexpression of genes relevant to PD, particularly α-synuclein. It may not be realistic to obtain a single animal model that completely reproduces every feature of a human disease as complex as PD. Nevertheless, compared with mice with the same mutations, many genetic rat animal models of PD better reproduce key aspects of PD including progressive loss of dopaminergic neurons in the substantia nigra, locomotor behavior deficits, and age-dependent formation of abnormal α-synuclein protein aggregates. Here we briefly review new developments in genetic rat models of PD that may have greater potential for identifying underlying mechanisms, for discovering novel therapeutic targets, and for developing greatly needed treatments to slow or halt disease progression.
© 2018 International Parkinson and Movement Disorder Society. © 2018 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  DJ-1; LRRK2; Parkin PINK1; Parkinson's disease; knockout; model; neurotoxin; rat; synuclein; transgenic; viral

Mesh:

Substances:

Year:  2018        PMID: 29418019      PMCID: PMC5992003          DOI: 10.1002/mds.27296

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  137 in total

1.  FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease.

Authors:  Anke Van der Perren; Francesca Macchi; Jaan Toelen; Marianne S Carlon; Michael Maris; Henriette de Loor; Dirk R J Kuypers; Rik Gijsbers; Chris Van den Haute; Zeger Debyser; Veerle Baekelandt
Journal:  Neurobiol Aging       Date:  2015-01-21       Impact factor: 4.673

2.  α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.

Authors:  W Peelaerts; L Bousset; A Van der Perren; A Moskalyuk; R Pulizzi; M Giugliano; C Van den Haute; R Melki; V Baekelandt
Journal:  Nature       Date:  2015-06-10       Impact factor: 49.962

3.  Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.

Authors:  Andrew B West; Rita M Cowell; João P L Daher; Mark S Moehle; Kelly M Hinkle; Heather L Melrose; David G Standaert; Laura A Volpicelli-Daley
Journal:  J Comp Neurol       Date:  2014-04-12       Impact factor: 3.215

4.  Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease.

Authors:  Linda Vercammen; Anke Van der Perren; Elisabetta Vaudano; Rik Gijsbers; Zeger Debyser; Chris Van den Haute; Veerle Baekelandt
Journal:  Mol Ther       Date:  2006-08-17       Impact factor: 11.454

5.  The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.

Authors:  Oleg S Gorbatyuk; Shoudong Li; Layla F Sullivan; Weijun Chen; Galina Kondrikova; Fredric P Manfredsson; Ronald J Mandel; Nicholas Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

6.  Evidence for early and progressive ultrasonic vocalization and oromotor deficits in a PINK1 gene knockout rat model of Parkinson's disease.

Authors:  Laura M Grant; Cynthia A Kelm-Nelson; Breanna L Hilby; Katherine V Blue; Eunice S Paul Rajamanickam; Joshua D Pultorak; Shelia M Fleming; Michelle R Ciucci
Journal:  J Neurosci Res       Date:  2015-07-31       Impact factor: 4.164

7.  Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration.

Authors:  Suzana Gispert; Filomena Ricciardi; Alexander Kurz; Mekhman Azizov; Hans-Hermann Hoepken; Dorothea Becker; Wolfgang Voos; Kristina Leuner; Walter E Müller; Alexei P Kudin; Wolfram S Kunz; Annabelle Zimmermann; Jochen Roeper; Dirk Wenzel; Marina Jendrach; Moisés García-Arencíbia; Javier Fernández-Ruiz; Leslie Huber; Hermann Rohrer; Miguel Barrera; Andreas S Reichert; Udo Rüb; Amy Chen; Robert L Nussbaum; Georg Auburger
Journal:  PLoS One       Date:  2009-06-03       Impact factor: 3.240

Review 8.  Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases.

Authors:  Ronald Melki
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

9.  Genetic basis of Parkinson's disease: inheritance, penetrance, and expression.

Authors:  Claudia Schulte; Thomas Gasser
Journal:  Appl Clin Genet       Date:  2011-06-01

10.  Structural and functional characterization of two alpha-synuclein strains.

Authors:  Luc Bousset; Laura Pieri; Gemma Ruiz-Arlandis; Julia Gath; Poul Henning Jensen; Birgit Habenstein; Karine Madiona; Vincent Olieric; Anja Böckmann; Beat H Meier; Ronald Melki
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  21 in total

Review 1.  Quantitative Rodent Brain Receptor Imaging.

Authors:  Kristina Herfert; Julia G Mannheim; Laura Kuebler; Sabina Marciano; Mario Amend; Christoph Parl; Hanna Napieczynska; Florian M Maier; Salvador Castaneda Vega; Bernd J Pichler
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

2.  Metabolomics Analyses from Tissues in Parkinson's Disease.

Authors:  Fatema Bhinderwala; Shulei Lei; Jade Woods; Jordan Rose; Darrell D Marshall; Eli Riekeberg; Aline De Lima Leite; Martha Morton; Eric D Dodds; Rodrigo Franco; Robert Powers
Journal:  Methods Mol Biol       Date:  2019

3.  Laryngeal muscle biology in the Pink1-/- rat model of Parkinson disease.

Authors:  Tiffany J Glass; Cynthia A Kelm-Nelson; John A Russell; John C Szot; Jacob M Lake; Nadine P Connor; Michelle R Ciucci
Journal:  J Appl Physiol (1985)       Date:  2019-03-07

Review 4.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

5.  Psychological Stress Phenocopies Brain Mitochondrial Dysfunction and Motor Deficits as Observed in a Parkinsonian Rat Model.

Authors:  Mariana Grigoruţă; Alejandro Martínez-Martínez; Raul Y Dagda; Ruben K Dagda
Journal:  Mol Neurobiol       Date:  2019-12-14       Impact factor: 5.590

6.  Enhanced Susceptibility of PINK1 Knockout Rats to α-Synuclein Fibrils.

Authors:  Rose B Creed; Matthew S Goldberg
Journal:  Neuroscience       Date:  2020-04-27       Impact factor: 3.590

7.  A New Paradigm for Training Hyperactive Dopamine Transporter Knockout Rats: Influence of Novel Stimuli on Object Recognition.

Authors:  Natalia P Kurzina; Anna B Volnova; Irina Y Aristova; Raul R Gainetdinov
Journal:  Front Behav Neurosci       Date:  2021-04-22       Impact factor: 3.558

8.  Longitudinal assessment of skilled forelimb motor impairments in DJ-1 knockout rats.

Authors:  Camilo A Sanchez; Jackson Brougher; Deepika G Krishnan; Catherine A Thorn
Journal:  Behav Brain Res       Date:  2022-01-29       Impact factor: 3.332

Review 9.  A Systematic Review of Oropharyngeal Dysphagia Models in Rodents.

Authors:  Han-Na Kim; Ji-Youn Kim
Journal:  Int J Environ Res Public Health       Date:  2021-05-07       Impact factor: 3.390

10.  Detergent-insoluble inclusion constitutes the first pathology in PFN1 transgenic rats.

Authors:  Guixiu Yuan; Shiquan Cui; Xuan Chen; Haochang Song; Cao Huang; Jianbin Tong; Zhentin Yuan; Lin Yu; Xinrui Xiong; Jihe Zhao; Bo Huang; Qinxue Wu; Yibo Zhou; Gong Chen; Hongxia Zhou; Xu-Gang Xia
Journal:  J Neurochem       Date:  2020-08-12       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.